Patent application number | Description | Published |
20080255045 | Modified FGF-21 Polypeptides and Their Uses - Modified FGF-21 polypeptides and uses thereof are provided. | 10-16-2008 |
20090208454 | MODIFIED INTERFERON BETA POLYPEPTIDES AND THEIR USES - Modified interferon beta polypeptides and uses thereof are provided. | 08-20-2009 |
20100035812 | Modified Bovine G-CSF Polypeptides And Their Uses - Modified bovine G-CSF polypeptides and uses thereof are provided. | 02-11-2010 |
20100135959 | Human Interferon Molecules and Their Uses - Modified human interferon polypeptides and uses thereof are provided. | 06-03-2010 |
20100298212 | Modified Insulin Polypeptides and Their Uses - Modified insulin polypeptides and their uses thereof are provided | 11-25-2010 |
20110172401 | Modified FGF-21 Polypeptides and Their Uses - Modified FGF-21 polypeptides and uses thereof are provided. | 07-14-2011 |
20110178029 | Modified Human Apolipoprotein A-1 and Their Uses - Modified human apolipoprotein A-I polypeptides and uses thereof are provided. | 07-21-2011 |
20120046229 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES - Modified relaxin polypeptides and their uses thereof are provided | 02-23-2012 |
20120149636 | Modified Leptin Polypeptides and Their Uses - Modified human leptin polypeptides and uses thereof are provided. | 06-14-2012 |
20120197006 | MODIFIED INTERFERON BETA POLYPEPTIDES AND THEIR USES - Modified interferon beta polypeptides and uses thereof are provided. | 08-02-2012 |
20120283172 | MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES - Modified porcine somatotropin polypeptides and uses thereof are provided. | 11-08-2012 |
20130150564 | Modified FGF-21 Polypeptides and Their Uses - Modified FGF-21 polypeptides and uses thereof are provided. | 06-13-2013 |
20130237481 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES - Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided. | 09-12-2013 |
20140194357 | Modified Relaxin Polypeptides and Their Uses - Modified relaxin polypeptides and their uses thereof are provided | 07-10-2014 |
20150031864 | Modified Adiponectin Polypeptides and Their Uses - Modified adiponectin polypeptides and uses thereof are provided. | 01-29-2015 |
20150080559 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives - Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses. | 03-19-2015 |